GRÜNENTHAL LICENSES EXCLUSIVE SOUTH KOREAN RIGHTS TO QUTENZA® TO BCWORLD PHARM

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Medicine

More Like This

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT

APOTEX LICENSES EXCLUSIVE CANADIAN RIGHTS TO QUTENZA® FROM GRÜNENTHAL

GRÜNENTHAL PRESENTS PHASE III RESULTS FOR QUTENZA® IN POST-SURGICAL NEUROPATHIC PAIN AT IASP 2026 WORLD CONGRESS ON PAIN

GRÜNENTHAL PARTNERS WITH DKSH TO BRING FOUR IMPORTANT PAIN MEDICINES TO EIGHT NEW MARKETS IN ASIA-PACIFIC

PR Newswire associated0

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)

QPS Holdings, LLC divests its Neuropharmacology Business Unit

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026